HC Wainwright reiterated their buy rating on shares of Immunome (NASDAQ:IMNM – Free Report) in a research note published on Thursday morning, Marketbeat.com reports. The firm currently has a $40.00 price objective on the stock.
A number of other research analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Truist Financial raised their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Barclays began coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target for the company. Citigroup reiterated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.
Check Out Our Latest Analysis on Immunome
Immunome Stock Performance
Immunome (NASDAQ:IMNM – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Sell-side analysts predict that Immunome will post -2.38 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Max Rosett sold 60,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $19.85, for a total transaction of $1,091,750.00. Following the sale, the insider directly owned 15,805 shares of the company’s stock, valued at $313,729.25. This represents a 77.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 682,310 shares of company stock worth $15,675,566. Insiders own 7.21% of the company’s stock.
Institutional Investors Weigh In On Immunome
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Integrated Wealth Concepts LLC purchased a new stake in Immunome in the 2nd quarter valued at about $27,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Immunome during the second quarter worth approximately $576,000. California State Teachers Retirement System raised its stake in shares of Immunome by 1,958.0% during the second quarter. California State Teachers Retirement System now owns 2,293,478 shares of the company’s stock valued at $48,599,000 after acquiring an additional 2,182,034 shares in the last quarter. Readystate Asset Management LP raised its stake in shares of Immunome by 23.3% during the second quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock valued at $34,027,000 after acquiring an additional 303,958 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Immunome during the second quarter valued at approximately $552,000. Institutional investors own 44.58% of the company’s stock.
About Immunome
Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.
Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.
Read More
- Five stocks we like better than Immunome
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
